Therapeutic Areas

Endocrine and Metabolic Disease Clinical Development Expertise

Overcoming complexities to bring more metabolic disease treatments to market successfully. 

Metabolic and endocrine diseases are a rising therapy area focus for clinical research due to the high demand for novel therapies that are challenged with proving safety and efficacy. The development process is complicated and full of unknowns, and even the best metabolic therapeutic might not make it to the patients that need it, not because it does not work but because the design, data collection, and analysis were not done right. 

 At Veristat, we have assembled an extraordinary team of scientific-minded experts who have mastered the complexities of running metabolic disease trials. Our team has supported 300+ projects for endocrine/metabolic disorder treatments and the preparation of 30+ marketing applications - 60% of which have been approved or authorized so far! 

Success with Lifestyle, Genetic, and Rare Metabolic Therapies

We strive to advance your novel metabolic therapies from Phase I-III clinical development to market with confidence.

Our experienced teams are poised to plan and implement these efforts quickly, providing:     

Proven Expertise for Success

300+

Endocrine/Metabolic Projects

> 250

Projects for infectious disease treatments and vaccines

> 70%

Genetic Disorders

Explore Our Endocrine Experience

Get the right strategic consultation, clinical program implentation, regulatory approval registration, and post-marketing support for endocrine and metabolic therapies based upon our extensive first-hand knowlege.

Breadth of Therapy Indications
Achondropasia Gaucher Disease Lipodystrophy
Adrenoleukodystrophy (ALD) and Thalassemia Generalized Lipodystrophy Lysosomal Acid Lipase (LAL)
Alpha-mannosidosis (AM) Gout (Hyperuricemia) Maroteaux-Lamy Syndrome
Anorexia Growth Hormone Deficiencies/Abnormalities Molybdenum Cofactor Deficiency
Bardet-Biedl Syndrome and Alstrom Syndrome Hereditary ATTR (hATTR) Amyloidosis Mucopolysaccharidosis type IIIB
Cerebral Adrenoleukodystrophy Homocystinuria Multiple Lysosomal Storage Disorders
Chronic Pancreatitis Homozygous Familial Hypercholesterolemia (HoFH) Non-Alcoholic Steatohepatitis (NASH)
Congenital Adrenal Hyperplasia Hypercholesterolemia Obesity
Diabetes Hyperoxaluria Pharmacodynamic Markers
Dyslipidemia Hypertriglyceridemia POMC deficiency
Fabry Disease Hypoleptinemic Dysmetabolic Disorder Pompe Disease
Familial Amyloid Polyneuropathy Hypoparathyroidism Pyruviate Kinase Deficiency
Familial Chylomicronemia Syndrome (FCS) Immunoglobulin A (IgA) Nephropathy Vasomotor symptoms (VMS)

Learn More with These Resources

Newsletter

Is Your Trial Stuck?

Case Study

Preparing Data for the Marketing Authorization Application ...

Conference Presentation

Turning Sponsor/CRO Relationships into Partnerships for ...